SB 509

Drug Profile

SB 509

Alternative Names: hVEGF-A; SB-509; VEGF activator zinc finger protein

Latest Information Update: 12 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sangamo BioSciences
  • Class Gene therapies; Neuroprotectants; Zinc finger DNA binding proteins
  • Mechanism of Action Gene transference; Genetic transcription stimulants; Vascular endothelial growth factor A expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Brain injuries; Diabetic neuropathies; Spinal cord injuries; Stroke

Most Recent Events

  • 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
  • 03 Oct 2011 Discontinued - Phase-II for Amyotrophic lateral sclerosis in USA (IM)
  • 03 Oct 2011 Discontinued - Phase-II for Diabetic neuropathies in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top